Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)

被引：0
|
作者：
Costantini, Adrien [1 ]
Corny, Jennifer [2 ]
Fallet, Vincent [1 ]
Renet, Sophie [2 ]
Friard, Sylvie [3 ]
Chouaid, Christos [4 ]
Duchemann, Boris [5 ]
Giroux-Leprieur, Etienne [6 ]
Taillade, Laurent [7 ]
Doucet, Ludovic [8 ]
Nguenang, Marina [9 ]
Jouveshomme, Stephane [10 ]
Wislez, Marie [1 ]
Tredaniel, Jean [10 ]
Cadranel, Jacques [1 ]
机构：
[1] Hop Tenon, Serv Pneumol, Paris, France
[2] Grp Hosp Paris St Joseph, Pharm Clin, Paris, France
[3] Hop Foch, Serv Pneumol, Suresnes, France
[4] Ctr Hosp Intercommunal Creteil, Serv Pneumol, Creteil, France
[5] Hop Avicenne, Serv Oncol Med, Bobigny, France
[6] Hop Ambroise Pare, Serv Pneumol & Oncol, Boulogne Billancourt, France
[7] Hop La Pitie Salpetriere, Serv Oncol Med, Paris, France
[8] Hop St Louis, Serv Oncol Med, Paris, France
[9] Hop Bichat Claude Bernard, Serv Pneumol C, Paris, France
[10] Grp Hosp Paris St Joseph, Serv Pneumol, Paris, France
来源：
EUROPEAN RESPIRATORY JOURNAL | 2018年 / 52卷
关键词：
D O I：
10.1183/13993003.congress-2018.PA2808
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2808
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Evaluation of Disease-Related Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel
    Gralla, Richard J.
    Coon, Cheryl
    Taylor, Fiona
    Penrod, John R.
    Derosa, Michael
    Dastani, Homa
    Orsini, Lucinda
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S233 - S234
  • [42] The relevance of CEA and CYFRA21-1 as predictive factors in nivolumab treated advanced non-small cell lung cancer (NSCLC) patients
    Dal Bello, M. G.
    Filiberti, R. A.
    Rijavec, E.
    Genova, C.
    Barletta, G.
    Rossi, G.
    Biello, F.
    Distefano, R.
    Orengo, A. M.
    Alama, A.
    Coco, S.
    Vanni, I.
    Tagliamento, M.
    Mussap, M.
    Grossi, F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 161 - 161
  • [43] The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Dal Bello, Maria Giovanna
    Filiberti, Rosangela
    Rijavec, Erka
    Genova, Carlo
    Barletta, Giulia
    Rossi, Giovanni
    Biello, Federica
    Distefano, Roberta
    Orengo, Anna Maria
    Alama, Angela
    Coco, Simona
    Vanni, Irene
    Mussap, Michele
    Grossi, Francesco
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S827 - S828
  • [44] Viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients with advanced non-small cell lung cancer (NSCLC).
    Morgensztern, Daniel
    Bazhenova, Lyudmila
    Waqar, Saiama N.
    McDermott, Lori
    Hutchins, Jeff
    Harb, Wael
    Pennell, Nathan
    Cohen, Roger B.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 101 - 101
  • [45] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [46] "Realworld" application of nivolumab and the impact of performance status on outcomes of in patients with advanced non-small cell lung cancer (NSCLC)
    Abbas, Nazim
    Roy, Amitesh
    Klevansky, Myron
    Vatandoust, Sina
    Kichenadasse, Ganessan
    Koczwara, Bogda
    Sukumaran, Shawgi
    Karapetis, Chris
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 82 - 82
  • [47] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
  • [48] Examination of patients with advanced non-small cell lung cancer (NSCLC) responding to nivolumab monotherapy over 1 year
    Nakajima, Saki
    Watanabe, Satoshi
    Utsunomiya, Takuhide
    Yoshinoya, Kiyokazu
    Honda, Hidehiro
    Yamamoto, Suguru
    Kudo, Keita
    ANNALS OF ONCOLOGY, 2022, 33 : S536 - S536
  • [49] Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)
    Caponnetto, S.
    Mancini, M.
    Manai, C.
    Magri, V.
    Iannantuono, G. M.
    Pellegrino, D.
    Mosillo, C.
    Piesco, G.
    Pomati, G.
    Scagnoli, S.
    Urbano, F.
    Verkhovskaya, S.
    Barchiesi, G.
    Zancla, S.
    Cortesi, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer
    Enomoto, T.
    Tamiya, A.
    Matsumoto, K.
    Adachi, Y.
    Azuma, K.
    Inagaki, Y.
    Kouno, S.
    Taniguchi, Y.
    Saijo, N.
    Okishio, K.
    Atagi, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 28 - 28
12345